Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. - Wikidata - wikimedia - TriplyDB

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.

http://www.wikidata.org/entity/Q34478557

about

Acetylation is indispensable for p53 activation Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization Chemical Variations on the p53 Reactivation Theme Novel Implications of DNA Damage Response in Drug Resistance of Malignant Cancers Obtained from the Functional Interaction between p53 Family and RUNX2 Direct and Propagated Effects of Small Molecules on Protein-Protein Interaction Networks The important molecular markers on chromosome 17 and their clinical impact in breast cancer Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53 Quantification of HER family receptors in breast cancer Small molecule compounds targeting the p53 pathway: are we finally making progress?The Numb/p53 circuitry couples replicative self-renewal and tumor suppression in mammary epithelial cells.Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development The p53 pathway as a target in cancer therapeutics: obstacles and promise The role of p53 in cancer drug resistance and targeted chemotherapy Role of E3 ubiquitin ligases in gastric cancer CDK8 is a stimulus-specific positive coregulator of p53 target genes PAC-1 activates procaspase-3 in vitro through relief of zinc-mediated inhibition Procaspase-3 activation as an anti-cancer strategy: structure-activity relationship of procaspase-activating compound 1 (PAC-1) and its cellular co-localization with caspase-3 Hdmx modulates the outcome of p53 activation in human tumor cells The p53 circuit board Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme The pharmacodynamics of the p53-Mdm2 targeting drug Nutlin: the role of gene-switching noise Systems biology analysis reveals role of MDM2 in diabetic nephropathy Modes of p53 regulation Implementation of a 220,000-compound HCS campaign to identify disruptors of the interaction between p53 and hDM2 and characterization of the confirmed hits.Eukaryotic translation elongation factor 1-alpha 1 inhibits p53 and p73 dependent apoptosis and chemotherapy sensitivity An integrative in silico approach for discovering candidates for drug-targetable protein-protein interactions in interactome data Design, synthesis, and evaluation of an alpha-helix mimetic library targeting protein-protein interactions.Assessing the druggability of protein-protein interactions by a supervised machine-learning method.The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients Identification and characterization of the first small molecule inhibitor of MDMX Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment.Pre-clinical validation of a selective anti-cancer stem cell therapy for Numb-deficient human breast cancers.Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2.Targeting tumor suppressor networks for cancer therapeutics.Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms.Argininosuccinate synthase 1 is an intrinsic Akt repressor transactivated by p53

P2860

Q24313477-AC634AE9-345B-467F-AB6A-398B9D59925D Q24650175-3DDAD272-646C-4A1B-8856-ADC19419E60E Q24651380-D42DA071-EEC1-4895-B33B-77239749B121 Q24669694-B8556083-0A0C-4774-8C90-B05CD0EC2AA7 Q26749008-E8B3BD57-264B-4DB1-96A2-FABAA699E9EE Q26777988-F4B5C894-D6E8-4072-B0E8-A0582E688E70 Q26784027-A5AFE655-779B-4087-A234-A342090B8A34 Q26859002-BAB03184-471C-42A0-A02A-BD114E421F33 Q27006998-C3169DA4-079C-4E90-B50E-915663896367 Q27015506-7083FA26-2C15-4CC1-BB51-888184011378 Q27027835-88E21EE4-0BD4-4304-8C9C-C1A5A8823CD3 Q27309278-45212D5C-AD54-4044-B2B9-B4AD38F7E0FB Q27670558-A1BE528E-D2AF-43CA-BA51-83D0BB450DFE Q27679680-6F6543DC-C182-4E72-8FA1-674655BE799E Q27684199-383B1087-5C29-44BD-9DD7-D1827DC5B0CB Q27690770-3FBE4EE6-77DD-494F-8CE2-534251BED371 Q28072553-44511399-E5FA-4BA3-BFD4-AB0B0D3C47C0 Q28082575-E400EF08-DDC6-45DF-940F-CCF340266DC7 Q28235350-641431CB-F684-434F-9FD4-BB00DDF79103 Q28237935-7A8CCEF4-1DAB-4E15-A883-30EDC569F2BA Q28256422-86B68607-404F-4A61-AF77-0FA58B29814C Q28257444-5792DFCF-089A-44B2-9DDB-D75D5AB4B79D Q28259725-7063A9ED-F681-4730-B737-25E216D185E8 Q28477660-56894176-B2A8-42C2-B633-F16B929D667D Q28542661-C9C47E7B-F67D-438B-ABD2-E6A27E73C1E3 Q28821589-BCE6450E-5716-430A-B701-168B616CACEC Q29615657-DC14D0B4-7493-48AD-B87B-BCEB12C81826 Q30985752-653E511F-5659-40B3-8DFA-F2B6BC70E59D Q31121002-4052876F-1A6E-416C-964D-26FC30CE5AD5 Q31122058-BBF611EF-9D3B-4014-8E29-8F6291A018B2 Q33424678-87148860-2A61-495C-AAA5-4C17C10EECEF Q33496355-3213231B-CFDB-4D9D-B6D9-F92D08080D8A Q33503737-025F9A55-ACD8-45D9-BFF6-15815D29B689 Q33524716-5BE90B19-BDDD-4574-9581-8A03F8CCE997 Q33533630-85D465A9-F2B8-4172-B41D-7457F949DC29 Q33626025-396D2AC9-F802-4D43-95F1-370C02F3895B Q33642043-B7A77D72-4761-4FCB-BE52-8230FA0E24F7 Q33657519-C3C0FD9C-7A0E-42CF-AEED-417023D89EBB Q33659512-2EF2D499-2E73-42A8-B0E2-CFF7F4AFEEC0 Q33708112-C39747DD-6DF6-4F83-9A18-9CD7F538D910

P2860

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.

http://www.wikidata.org/entity/Q34478557

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Small-molecule MDM2 antagonist ...... cer: implications for therapy.

@ast

Small-molecule MDM2 antagonist ...... cer: implications for therapy.

@en

Small-molecule MDM2 antagonist ...... cer: implications for therapy.

@nl

type

label

Small-molecule MDM2 antagonist ...... cer: implications for therapy.

@ast

Small-molecule MDM2 antagonist ...... cer: implications for therapy.

@en

Small-molecule MDM2 antagonist ...... cer: implications for therapy.

@nl

prefLabel

Small-molecule MDM2 antagonist ...... cer: implications for therapy.

@ast

Small-molecule MDM2 antagonist ...... cer: implications for therapy.

@en

Small-molecule MDM2 antagonist ...... cer: implications for therapy.

@nl

P1433

Q34478557-735832A6-D74C-400B-A923-DC1DAAB5F2CB

P1476

Q34478557-C2B626D3-0D97-4EF5-B410-0AF821125B1F

P2093

Q34478557-059D8203-D11C-4AD7-954A-A01EACADD1CD

Q34478557-1B11BADF-A38B-4F5D-9574-7D090349FBD4

Q34478557-1DCCAD90-7D7D-4287-8943-814B95462A9A

Q34478557-1F14D8C2-8A82-4DC3-A980-DDB5C6A07C68

Q34478557-32BB1812-A2D9-4B14-B1C7-2E6B47B3F194

Q34478557-4D662735-E81F-4568-9590-2AE967CA1280

Q34478557-5F980DC4-1210-4C73-841A-E4D5172EE82C

Q34478557-6DE261FE-415F-41D8-B8E5-EDCFF31B314E

Q34478557-A1818617-6D92-4B5C-99F9-F558FF362959

Q34478557-CA92AC25-C4C9-4927-B93C-12CE3C6166D9

P2860

Q34478557-1595852F-225C-469C-B502-6A0D51C3A005

Q34478557-180AB750-7E77-4FD1-B5C3-468D8A864D1E

Q34478557-220DC5B5-8696-4981-BCE8-5E3FC29A3BBB

Q34478557-33DBF787-5E55-4C3B-8CA7-6FCFBB708CEC

Q34478557-36C54A2A-14E5-4D9F-8C09-0791C53F51DA

Q34478557-37EEBEE3-5F60-4532-B117-D32F07B97108

Q34478557-3FB39721-1CAC-4301-B85A-2483EBC33CC5

Q34478557-4310961C-837D-404F-BCCE-B1D9A4106A61

Q34478557-522D19BC-1FD8-46BF-B0C0-D04C91FE1824

Q34478557-528656A7-197B-47F0-A08B-7D05372AC2C0

P304

Q34478557-94C95B1B-A123-49C7-BD55-377618348F40

P31

Q34478557-96F41ADA-1F35-4FD6-9532-9199C939D785

P356

Q34478557-B7B61271-04B8-4F53-9FBA-BA728DAE6941

P407

Q34478557-B8A29EF6-E76E-4272-B4F6-7295948DFF09

P433

Q34478557-2F057061-2EAB-4634-BA1F-313917C680D8

P478

Q34478557-722BB021-10B2-460D-9228-9395C6A4FEEF

P577

Q34478557-BCCCA14E-2E2F-4BC8-B040-3763FC005E84

P5875

Q34478557-02579238-7DD8-4956-A2C6-9580C9E6CC66

P698

Q34478557-7B089013-7E26-4B01-A0CB-56223B63917E

P932

Q34478557-568E5C46-9ED1-42BE-9C6D-7DBC11D19AE1

P356

PNAS.0507493103

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Small-molecule MDM2 antagonist ...... cer: implications for therapy.

@en

P2093

Binh T Vu

http://www.w3.org/2001/XMLSchema#string

Brian Higgins

http://www.w3.org/2001/XMLSchema#string

Christian Tovar

http://www.w3.org/2001/XMLSchema#string

David C Heimbrook

http://www.w3.org/2001/XMLSchema#string

Holly Hilton

http://www.w3.org/2001/XMLSchema#string

James Rosinski

http://www.w3.org/2001/XMLSchema#string

Kathryn Packman

http://www.w3.org/2001/XMLSchema#string

Kenneth Kolinsky

http://www.w3.org/2001/XMLSchema#string

Lyubomir T Vassilev

http://www.w3.org/2001/XMLSchema#string

Ola Myklebost

http://www.w3.org/2001/XMLSchema#string

P2860

Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

p53, the cellular gatekeeper for growth and division

WAF1, a potential mediator of p53 tumor suppression

Surfing the p53 network

Functions of the MDM2 oncoprotein

MDM2--master regulator of the p53 tumor suppressor protein

p21 is a universal inhibitor of cyclin kinases

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

p53 mutations in human cancers

P304

1888-1893

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0507493103

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P577

2006-01-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7329515

http://www.w3.org/2001/XMLSchema#string

P698

16443686

http://www.w3.org/2001/XMLSchema#string

P932

1413632

http://www.w3.org/2001/XMLSchema#string